Incrementare le conoscenze sull’Osteogenesis Imperfecta (OI) raccogliendo ed integrando dati epidemiologici, informazioni genetiche e performance funzionale dall’analisi del movimento – OR6

Title

Code

4FRAILTY

Type

Sperimentale

Start Year

2022

Status

In Corso

Principal Investigator

051-6366519, 051-6366681

luca.sangiorgi@ior.it

Sangiorgi Luca, MD

Director

Rare skeletal disorders

Operational unit that carry out the study

complex unit

Malattie rare scheletriche

Director

Sangiorgi Luca, MD

Go to the details >>

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio clinico prot. 4FRAILTY

Friday 3 June 2022, 13:58

PG0008972_2022_prot. 4FRAILTY.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

Incrementare le conoscenze sull’Osteogenesis Imperfecta (OI) raccogliendo ed integrando dati epidemiologici, informazioni genetiche e performance funzionale dall’analisi del movimento – OR6

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

Incrementare le conoscenze sull’Osteogenesis Imperfecta (OI) raccogliendo ed integrando dati epidemiologici, informazioni genetiche e performance funzionale dall’analisi del movimento – OR6

Principal Investigator

Operational unit that carry out the study

Documents and Videos attachament

You might also be interested in